Attached files
| file | filename |
|---|---|
| EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-2016033110qex311.htm |
| EX-32.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-2016033110qex321.htm |
| EX-10.2 - AMENDED AND RESTATED 2016/20 LONG-TERM INCENTIVE PLAN - PDL BIOPHARMA, INC. | pdli-2016033110qex102.htm |
| EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-2016033110qex312.htm |
| 10-Q - 10-Q - PDL BIOPHARMA, INC. | pdli-2016033110qdoc.htm |
| EX-10.1 - AMENDED AND RESTATED 2016 ANNUAL BONUS PLAN - PDL BIOPHARMA, INC. | pdli-2016x033110qex101.htm |
Exhibit 12.1
PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(Amount in thousands, except for ratios)
For the Three Months Ended March 31, 2016 | ||||||||||||||||||||||||
2011 | 2012 | 2013 | 2014 | 2015 | ||||||||||||||||||||
Earnings: | ||||||||||||||||||||||||
Income before income taxes | $ | 307,428 | $ | 327,133 | $ | 401,876 | $ | 501,272 | $ | 530,138 | $ | 88,841 | ||||||||||||
Add: fixed charges | 36,153 | 29,097 | 24,931 | 39,274 | 27,123 | 4,566 | ||||||||||||||||||
Earnings | $ | 343,581 | $ | 356,230 | $ | 426,807 | $ | 540,546 | $ | 557,261 | $ | 93,407 | ||||||||||||
Fixed Charges: | ||||||||||||||||||||||||
Interest expense1 | $ | 36,102 | $ | 29,036 | $ | 24,871 | $ | 39,211 | $ | 27,059 | $ | 4,550 | ||||||||||||
Estimated interest portion of rent expense2 | 51 | 61 | 60 | 63 | 64 | 16 | ||||||||||||||||||
Fixed charges | 36,153 | $ | 29,097 | $ | 24,931 | $ | 39,274 | $ | 27,123 | $ | 4,566 | |||||||||||||
Ratio of earnings to fixed charges | 9.50 | 12.24 | 17.12 | 13.76 | 20.55 | 20.46 | ||||||||||||||||||
_____________________________________
1 Interest expense includes amortization of debt discount and expenses.
2 Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest and amortization of discount related to indebtedness.